Taxotere, Docetaxel Newswire (Page 9)

Taxotere, Docetaxel Newswire (Page 9)

Comprehensive Real-Time News Feed for Taxotere, Docetaxel (generic). (Page 9)

Results 161 - 180 of 1,573 in Taxotere, Docetaxel (generic)

  1. CHMP Issues a Positive Opinion on Janssena s ZYTIGA to Include Earlier Stage Prostate Cancer PatientsRead the original story w/Photo

    Oct 13, 2017 | Business Wire

    CHMP Recommends to Broaden Indication to Include the Treatment of Men with Newly Diagnosed High-Risk Metastatic Hormone-Sensitive Prostate Cancer )--Janssen-Cilag International NV today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended broadening the existing marketing authorisation for ZYTIGA plus prednisone / prednisolone to include an earlier stage of prostate cancer than its current indications.

    Comment?

  2. CHMP Issues A Positive Opinion On Janssen-Cilag International...Read the original story

    Oct 12, 2017 | BioSpace

    Janssen-Cilag International NV today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended broadening the existing marketing authorisation for ZYTIGA plus prednisone / prednisolone to include an earlier stage of prostate cancer than its current indications.

    Comment?

  3. Send Press Releases with GlobeNewswireRead the original story

    Oct 12, 2017 | GlobeNewswire

    Infinity and MedImmune Initiate Phase 1b Trial of IPI-504 in Combination With Taxotere in Patients With Advanced Solid Tumor Cancers

    Comment?

  4. Peripheral Neuropathy Can Be A Side Effect Of ChemotherapyRead the original story w/Photo

    Oct 10, 2017 | Cancer Treatment

    Early-stage breast cancer patients can develop peripheral neuropathy years after completing chemotherapy, according to researchers at UCLA, UC Davis, and other institutions. Initial research involved a systematic review of PN literature, and it revealed how little the post-chemotherapy PN issue has been studied.

    Comment?

  5. Easton Pharmaceuticals & Alliance Group Announces It Has Cleared...Read the original story

    Oct 9, 2017 | BioSpace

    Easton's JV partner, 1124123 Ontario Limited have been advised by its legal representation that it has cleared its last license exemption hurdles which clears a path for Alliance to grow, cultivate and distribute medical / recreational marijuana for the country of Canada. This has now resulted in Alliance Group bringing forward interim facility engineering plans with expectations of a completed greenhouse growing facility within 6 months which would be near the anticipated national launch date of recreational / medical marijuana for the country of Canada.

    Comment?

  6. Easton Pharmaceuticals & JV Partner Alliance Group Announces It Has...Read the original story w/Photo

    Oct 10, 2017 | Market Wire

    Easton's JV partner, 1124123 Ontario Limited have been advised by its legal representation that it has cleared its last license exemption hurdles which clears a path for Alliance to grow, cultivate and distribute medical / recreational marijuana for the country of Canada. This has now resulted in Alliance Group bringing forward interim facility engineering plans with expectations of a completed greenhouse growing facility within 6 months which would be near the anticipated national launch date of recreational / medical marijuana for the country of Canada.

    Comment?

  7. Contrasting Eagle Pharmaceuticals (EGRX) & The CompetitionRead the original story

    Oct 9, 2017 | AmericanBankingNews.com

    Eagle Pharmaceuticals is one of 19 publicly-traded companies in the "Specialty & Advanced Pharmaceuticals" industry, but how does it compare to its peers? We will compare Eagle Pharmaceuticals to related businesses based on the strength of its dividends, profitability, risk, analyst recommendations, earnings, institutional ownership and valuation. Eagle Pharmaceuticals' peers have higher revenue and earnings than Eagle Pharmaceuticals.

    Comment?

  8. Lung Cancer Therapeutics Market Segment-level analysisRead the original story w/Photo

    Oct 8, 2017 | PR-inside.com

    The Global Lung Cancer Therapeutics Market was worth $5.65 billion in 2016 and estimated to be growing at a CAGR of 6.7%, to reach $7.81 billion by 2021. Lung cancer is the second most commonly detected and has the highest death rate of all cancers in both men and women.

    Comment?

  9. Latin America Prostate Cancer Market to have positive long-term growth outlook 2016-21Read the original story w/Photo

    Oct 8, 2017 | PR-inside.com

    Latin America Prostate Cancer Market by Diagnostic Techniques, by Radiation Therapy, by Chemotherapy, and by Region - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts The Latin America Prostate Cancer Market was worth $5.28 billion in 2016 and estimated to be growing at a CAGR of 10.32%, to reach $8.63 billion by 2021. Prostate cancer is one of the serious health issues among men that has large socioeconomic impact on the society.

    Comment?

  10. Daniel P. Petrylak, MD, on Urothelial Carcinoma: Results of the RANGE TrialRead the original story w/Photo

    Oct 6, 2017 | Newswise

    Daniel P. Petrylak, MD, of Yale Cancer Center, discusses phase III study findings on docetaxel with or without ramucirumab in platinum-refractory advanced or metastatic urothelial carcinoma.

    Comment?

  11. Prostate Cancer Market A- Global Industry Perspective, Comprehensive...Read the original story

    Oct 4, 2017 | Emailwire.com

    Prostate Cancer Market by Diagnostic Techniques, by Surgery, by Radiation Therapy, by Chemotherapy, and by Region - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts The Global Prostate Cancer Market was worth $48 billion in 2016 and estimated to be growing at a CAGR of 9.5%, to reach $75.56 billion by 2021. The prostate cancer market has a high demand for novel drugs that concentrate on unmet needs such as improved survival time, less toxicity, better progression free survival, improved effectiveness, and lesser cost.

    Comment?

  12. Metastatic Breast Cancer Market: Shares and Strategies For Key Industry Players By 2020Read the original story w/Photo

    Oct 3, 2017 | PR-inside.com

    Metastatic breast cancer involves cases where the cancer has spread from the breasts to other organs in the human body, thereby resulting in malignancy. According to World Health organization in 2012, around 521,000 people died due to breast cancer and this number is expected to increase in the near future.

    Comment?

  13. Analyzing Eagle Pharmaceuticals (EGRX) and Its RivalsRead the original story w/Photo

    Oct 1, 2017 | The Breeze

    Eagle Pharmaceuticals is one of 19 public companies in the "Specialty & Advanced Pharmaceuticals" industry, but how does it weigh in compared to its rivals? We will compare Eagle Pharmaceuticals to similar businesses based on the strength of its earnings, risk, dividends, institutional ownership, valuation, analyst recommendations and profitability. 66.4% of shares of all "Specialty & Advanced Pharmaceuticals" companies are owned by institutional investors.

    Comment?

  14. Genentech??'s Perjeta Nabs FDA Priority Review for Early Breast CancerRead the original story

    Sep 28, 2017 | BioSpace

    Genentech, a member of the Roche Group , today announced the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application and granted Priority Review for PerjetaA , in combination with HerceptinA and chemotherapy , for adjuvant treatment of HER2-positive early breast cancer . The FDA is expected to make a decision on approval by January 28, 2018.

    Comment?

  15. FDA Grants Priority Review For Genentech??'s Perjeta (Pertuzumab) For ...Read the original story

    Sep 28, 2017 | BioSpace

    Genentech, a member of the Roche Group , today announced the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application and granted Priority Review for PerjetaA , in combination with HerceptinA and chemotherapy , for adjuvant treatment of HER2-positive early breast cancer . The FDA is expected to make a decision on approval by January 28, 2018.

    Comment?

  16. FDA Grants Priority Review for Genentech's Perjeta (Pertuzumab) for...Read the original story

    Sep 28, 2017 | Customer Interaction Solutions

    Genentech, a member of the Roche Group , today announced the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application and granted Priority Review for Perjeta , in combination with Herceptin and chemotherapy , for adjuvant treatment of HER2-positive early breast cancer . The FDA is expected to make a decision on approval by January 28, 2018.

    Comment?

  17. Analyzing Eagle Pharmaceuticals (EGRX) and Its CompetitorsRead the original story w/Photo

    Sep 28, 2017 | AmericanBankingNews.com

    Eagle Pharmaceuticals is one of 19 public companies in the "Specialty & Advanced Pharmaceuticals" industry, but how does it contrast to its competitors? We will compare Eagle Pharmaceuticals to similar businesses based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, earnings, valuation and risk. Eagle Pharmaceuticals currently has a consensus price target of $72.50, indicating a potential upside of 23.49%.

    Comment?

  18. FDA grants Priority Review for Roches Perjeta (pertuzumab) for...Read the original story

    Sep 28, 2017 | PressReleasePoint

    Roche today announced the US Food and Drug Administration has accepted the company's supplemental Biologics License Application and granted Priority Review for PerjetaA , in combination with HerceptinA and chemotherapy , for adjuvant treatment of HER2-positive early breast cancer . The FDA is expected to make a decision on approval by 28 January 2018.

    Comment?

  19. Malignant Pleural Effusion Treatment Market : Revenue, Price and Gross Margin Research Report 2025Read the original story

    Sep 27, 2017 | SBWire

    Mail Service Pharmacy Market: Snapshot Mail service pharmacy is swiftly becoming a highly used channel of distribution of pharmaceutical products to the consumers. Some of the leading players in the global mail service pharmacy market are propelling their services ahead of the game through high level quality improvements, addition of benefits and loyalty services, greater accountability, patient care, and consumer protection.

    Comment?

  20. Chemo-loaded nanoparticles target breast cancer that has spread to boneRead the original story w/Photo

    Sep 27, 2017 | PhysOrg Weblog

    Seeking new treatments for metastatic breast cancer, researchers have designed nanoparticles that carry chemotherapy and are targeted directly to tumors that have spread to bone. The strategy, developed in mouse studies at Washington University School of Medicine in St. Louis, lets chemotherapy penetrate the protective environment of bone and minimizes toxic side effects.

    Comment?